Related Experiment Video
Updated: Jun 19, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
HD-03/ES: a promising herbal drug for HBV antiviral therapy
Premashis Kar1, Mohammad Asim, Manash Pratim Sarma
1Department of Medicine, Maulana Azad Medical College, New Delhi, India. premashishkar@gmail.com
Insights
This study found that the herbal molecule HD-03/ES significantly reduced Hepatitis B virus (HBV) DNA and improved liver function in chronic HBV patients. Genotype A showed a better response to HD-03/ES treatment compared to genotype D.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic liver disease, particularly Hepatitis B virus (HBV) infection, poses a significant global health burden.
- Understanding HBV genotypes is crucial for predicting disease progression and treatment response.
- Antiviral herbal molecules are being explored as potential therapeutic agents for chronic HBV.
Purpose of the Study:
- To investigate the genotypes associated with chronic liver disease in HBV patients.
- To evaluate the efficacy of the antiviral herbal molecule HD-03/ES in treating chronic HBV.
- To assess the response of different HBV genotypes to HD-03/ES therapy.
Main Methods:
- A cohort of 51 chronic liver disease patients received HD-03/ES for 6 months.
- Monthly monitoring of liver function tests and HBV viral load (HBsAg, HBeAg, HBV DNA).
- Genotyping of HBV using PCR-RFLP at baseline and post-treatment.
Main Results:
- HD-03/ES therapy led to significant reductions in ALT levels and HBeAg/HBV DNA.
- Genotype D was prevalent (76.5%), followed by genotype A (33.5%).
- Patients with genotype A exhibited a significantly sharper decline in viral load compared to genotype D.
Conclusions:
- The majority of chronic HBV patients in this study were infected with genotype D.
- HD-03/ES demonstrated therapeutic potential in reducing HBV viral load, with a more pronounced effect observed in genotype A patients.
- Larger studies are warranted to validate these findings and confirm the therapeutic efficacy of HD-03/ES across different HBV genotypes.
Introduction:
The present study was designed to study the genotypes associated with different groups of chronic liver disease and to see their response to HD-03/ES (an antiviral herbal molecule) on chronic HBV patients.
Methods:
A total of 51 patients of chronic liver disease were recruited in the study and were given HD-03/ES, two capsules twice daily for 6 months. Liver function tests were done every month after initiating treatment. Serum was analyzed for HBsAg, HBeAg and HBV DNA and quantitative estimation of HBV at baseline, 4 and 6 months after therapy. The genotype of all the cases was also determined by PCR-RFLP method.
Results:
After 6 months of therapy with HD-03/ES, a significant reduction of ALT values from 71.2 + or - 16.3 to 36.4 + or - 6.8 and a significant HBeAg loss (27.4%) and HBV DNA loss (27.4%) was observed. Adverse effects were mild. Genotype D was found in 39 (76.5%) while genotype A was found in 12 (33.5%) cases, respectively. The mean reduction in viral load was observed from log(10) 7.1 + or - 1.8 copies/ml to log(10) 4.4 + or - 1.1 copies/ml. However, a sharp decline in viral load was observed in patients infected with genotype A (log(10) 6.8 + or - 2.5 to log(10) 4.9 + or - 1.8; P < 0.01) compared to genotype D (log(10) 7.0 + or - 2.6 to log(10) 5.9 + or - 3.5; P = 0.074).
Conclusion:
The study had shown that majority of the patients of chronic HBV related liver disease had genotype D. In additional, the molecule HD03/ES had a better therapeutic capability of lowering the HBV viral load in patients with genotype A, which needs to be validated in larger studies.
Related Concept Videos
Hepatitis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Rheumatic Heart Disease III: Medical Management
